Apoquel vs Cytopoint: At a Glance
Two modern allergy medications that work differently — here's how to choose.
Factor
| Factor | Apoquel (Oclacitinib) | Cytopoint (Lokivetmab) | Which Is Better? |
|---|---|---|---|
| How It Works | JAK inhibitor — blocks itch signal inside cells | Monoclonal antibody — neutralizes IL-31 (itch cytokine) | Different mechanisms, both effective |
| Administration | Daily pill (oral) | Injection at vet (every 4-8 weeks) | Apoquel: at-home convenience. Cytopoint: no daily pills |
| Onset | 4-24 hours | 24-48 hours | Apoquel slightly faster |
| Duration | 24 hours (daily dosing) | 4-8 weeks per injection | Cytopoint: less frequent dosing |
| Cost/Month | $60-$120 | $50-$150 (per injection) | Similar — depends on dog size and vet pricing |
| Side Effects | GI upset, increased infection risk (long-term) | Very few — rare injection site reaction | Cytopoint: fewer side effects |
Monthly Cost by Dog Size
Apoquel vs Cytopoint: How to Choose
| Dog won't take pills → Cytopoint (injection) | |
| Need relief TODAY → Apoquel (faster onset) | |
| Dog has history of infections → Cytopoint (fewer side effects) | |
| Want at-home treatment → Apoquel (daily pill) | |
| Forgetful with daily meds → Cytopoint (every 4-8 weeks) | |
| Budget-conscious → Compare prices; both similar | |
| Puppy under 12 months → Cytopoint (Apoquel not approved <12 months) | |
| Both medications can be used together in severe cases |
Cytopoint is a monoclonal antibody — it targets ONE specific itch signal (IL-31) without suppressing the broader immune system. Apoquel is a JAK inhibitor — it blocks multiple inflammatory pathways. Cytopoint is generally considered safer for long-term use, but both are effective.
Apoquel is NOT approved for dogs under 12 months of age. It can increase the risk of infections (demodectic mange, pneumonia) with long-term use. Regular bloodwork monitoring is recommended for dogs on Apoquel long-term.
Apoquel (oclacitinib) is a daily pill that blocks a set of immune signals behind allergic itching, often relieving itch within hours to a day or two, while Cytopoint (lokivetmab) is an injection given roughly every 4 to 8 weeks that targets one specific itch-triggering protein called IL-31 rather than a broader set of signals. Both treat allergic and atopic dermatitis in dogs, and the better fit depends on a dog's individual health history and how the vet wants to monitor treatment, not simply which drug is newer or more talked about.
Apoquel vs Cytopoint
Two different ways to interrupt the same itch signal
petstore.comHow the two options differ
Apoquel (oclacitinib)
A daily pill, a JAK inhibitor that blocks itch and inflammation signals, often given twice a day for 2 weeks then once daily.
Cytopoint (lokivetmab)
An injection given roughly every 4-8 weeks, a targeted antibody that blocks IL-31, the specific protein that triggers itch signals.
Questions worth asking your vet
Two dogs with the exact same allergic itch can end up on two completely different medications, and both can be the right call. The difference between Apoquel and Cytopoint isn't which one is "stronger," it's which itch signal each one is built to interrupt.
This matters because chronic itching from allergies is miserable for a dog and genuinely disruptive for a household, constant scratching, licked-raw paws, sleepless nights. Understanding how these two medications actually work helps you have a more useful conversation with your vet instead of just picking a name you've heard advertised.
Apoquel Interrupts a Whole Family of Itch Signals
Apoquel's active ingredient, oclacitinib, is a Janus kinase (JAK) inhibitor. It works by blocking JAK enzyme activity that a range of pruritogenic (itch-causing) and inflammatory signals, including interleukin-31, depend on to function. Because it blocks multiple pathways at once, it can address both the itch and some of the inflammation driving it, which is part of why it's typically started at a higher dose twice daily for the first two weeks before dropping to a once-daily maintenance dose.
As a daily oral pill, it requires consistent dosing and, since it affects broader immune signaling, a vet may recommend periodic bloodwork to monitor for effects on the immune system over long-term use.
Cytopoint Targets One Specific Messenger
Cytopoint's active ingredient, lokivetmab, works differently: it's a caninized monoclonal antibody, meaning it's engineered specifically for dogs, that binds directly to interleukin-31 (IL-31) and neutralizes it before it can activate the nerve pathways that cause itch. It does not have general anti-inflammatory or immunosuppressive activity the way Apoquel does; it's narrowly focused on this one itch-signaling protein.
Because it's given by injection roughly every 4 to 8 weeks rather than daily by mouth, it can be a simpler option for dogs who are difficult to pill consistently, or for owners who prefer fewer, longer-lasting doses over a daily habit.
Neither Choice Is Automatically the Better One
A dog with a health condition where broader immune suppression is a concern might do better on the more targeted Cytopoint. A dog whose itching comes with a lot of accompanying inflammation might respond more completely to Apoquel's wider mechanism. Cost structure differs too: a recurring injection every several weeks versus a daily pill adds up differently depending on your dog's size and your vet's dosing plan.
The real decision point isn't which drug sounds more advanced, it's which itch pathway your dog's particular allergy is running through, and that's a conversation for your vet, informed by your dog's full history, not a guess from a product name.
Veterinary pharmacology references describe oclacitinib (Apoquel) as a Janus kinase (JAK) inhibitor that blocks pruritogenic cytokines including IL-31 and other proinflammatory cytokines dependent on JAK1 or JAK3 activity, typically dosed at 0.4 to 0.6 mg/kg orally every 12 hours for 2 weeks before reducing to once-daily maintenance dosing. Lokivetmab (Cytopoint) is described as a caninized monoclonal antibody that binds and neutralizes interleukin-31, registered for reduction of pruritus in canine atopic and allergic dermatitis, typically dosed at 1 to 2 mg/kg by injection. Exact dosing for any individual dog is determined by the prescribing veterinarian.